MUSC Hollings Cancer Center

Program Requirements

Continuation in the K12 Paul Calabresi Career Development Award for Clinical Oncology Program is determined yearly based upon satisfactory research progress, professional effort, academic grades, and attendance and participation in required events.

1. Professional Effort
Calabresi Scholars are expected to devote 75% of their full-time effort (50% for surgeons), for two years, to the 
       training and clinical oncology research activities of the program. Scholars’ remaining effort may be devoted to
       other clinical or academic pursuits consistent with the award. However, salary supplementation may not be from
       federal funds unless specifically authorized by the federal program from which such funds are derived.

2. Mentorship
Developing a successful cancer research career requires strong relationships with mentors and a research team.
       Scholars will select three mentors, one primary mentor and two secondary mentors. Each mentoring team must 
       also include a practicing oncology MD.  All mentors must be pre-approved by the K12 Program’s leadership.
      Please click here for a list of approved mentors.

3. Program Milestones

 ♦ Within each Scholar’s career development plan, he/she will be
    expected to complete three different but related milestones. 
    Each MD Scholar will design and initiate a clinical cancer
    therapy trial to answer a biological hypothesis-based clinical   
    research question. Alternatively, PhD Scholars will be 
    charged to develop and conduct a correlative science study, 
    either basic or population science-based. As a second 
    milestone, at least two publishable research reports should 
    result from the Scholar’s studies. Finally, the Scholar will be 
    expected to create a fully developed grant application and 
    submit it to a funding agency (e.g., NIH, DOD, ACS).

4. Didactic Coursework and Research Seminars
This K12 Program includes a comprehensive didactic program in translational research methods including the 
       following courses:

A.   Principles of Cancer Biology (MD Scholars)/Introduction to Multidisciplinary Clinical Oncology
       (PhD Scholars)
B.   Methods in Clinical Cancer Research
C.   Translational Cancer “omics” and the Path to Personalized Medicine
D.   Principles of Targeted Cancer Drug Discovery and Development
E.   Methods and Outcomes in Cancer Population Sciences
F.   Cancer Immunotherapy: Lessons Learned and the Path Forward

Additionally, all Scholars will be required to take Ethical Issues in Clinical Research which meets requirements for Responsible Conduct in Research and attend workshops and seminars.

5. Three Areas of Research Focus
The K12 Paul Calabresi Clinical & Translational Oncology Training Program will emphasize three key areas of
       research training in specific pathways:

A.   Drug discovery/development with a focus on small molecule drug development
B.   Cancer immunotherapy including immunoglobulin, vaccine, and cellular therapies
C.   Population sciences driven by cancer epidemiology, health behavior research, and implementation science
Each Scholar will choose one of these pathways.
For more information on these focus areas, please click here.

6. Laboratory & Clinical Rotations

♦     Short Laboratory Rotations: In order to provide a breadth of applied experience required in conducting
       patient-oriented translational research, all Scholars will be required to complete one or more six-week laboratory
       rotations relevant to the track they have selected and/or career development goals that they have established. 
       Many of these rotations are linked with key shared resources and are intended to provide the Scholar with the
       opportunity to acquire specific technical expertise.

♦     Short Clinical Rotations: Scholars will be required to
       participate in clinic-based research rotations as well.  The
       purpose of these rotations is to provide exposure and
       experience in clinical investigation, as well as a focused  
       exposure to particular types of cancer patients. As part of the
       K12 Program, MD Scholars may participate up to three half-day 
       clinics as either short rotations (six weeks) or during longitudinal
       training for the duration of the Program.  MD Scholars will be
       expected to treat patients in the Phase I clinic for at least one of
       these half day clinics and can then chose up to two other 
       multidisciplinary disease clinics. PhD Scholars will be required
       to do at least three clinical research-related rotations.

♦     In Depth Clinical and Laboratory Training: Beginning in Quarter 2 or Quarter 3 of the first year of the 
       Scholar’s training program, he/she will immerse in a longitudinal clinical and laboratory experience that will
       last for the remainer of the time the Scholar is in the program. These experiences will
       form the foundation to complete the required milestones. Since the focus of the Program is primarily on the
       development of a patient-oriented researcher, it is not expected that the MD Scholars will become basic science
       researchers, but rather will learn to use assays, new technologies, and analyses that will enable the evaluation of
       pertinent clinical research questions in the laboratory. The Scholars will be expected to be familiar with the
       conduct, quality control, and interpretation of assays pertinent to their clinical research protocol. Likewise, PhD
       Scholars are expected to draw upon their clinical observations to formulate more informed correlative study
       designs.  The proportions of laboratory and clinical involvement may differ between these two classes 
       of Scholars, but all will participate in both activities during the longitudinal training period. 

7. National Meeting
K12 Clinical Oncology Scholars will be required to attend a national professional meeting each year.

      Grant Citations: All presentations and publications related to research funded by the K12 Paul
      Calabresi Clinical & Translational Oncology Training Program must cite the appropriate grant 
      award. The NIH funding acknowledgement for all publications and projects is:
    “This publication was supported by the National Cancer Institute of the National Institutes of
      Health, Grant Number K12 CA157688. The content is solely the responsibility of the authors
     and does not necessarily represent the official views of the NIH."


* This website is best viewed in Firefox or Chrome internet browsers.

You'll need Skype CreditFree via Skype